Xenetic Biosciences' Q1 royalty revenue rises, net loss narrows

Xenetic Biosciences

13/05/2026 13:13

Overview

US biopharma firm's Q1 2026 royalty revenue rose 36% yr/yr, driven by higher Takeda payments

Net loss for Q1 2026 narrowed 49% from prior year period

Company ended Q1 2026 with $7.3 mln in cash, continues to review strategic alternatives

Result Drivers

ROYALTY REVENUE GROWTH - Q1 royalty revenue rose 36% yr/yr, mainly due to increased payments from Takeda under a sublicense agreement

LOWER R&D COSTS - Research and development expenses fell 25% yr/yr, mainly due to reduced preclinical and exploratory study costs, partially offset by higher manufacturing development spending

REDUCED PERSONNEL AND SHARE-BASED COSTS - General and administrative expenses declined 1.4%, mainly due to lower personnel and share-based expenses, mostly offset by higher legal costs from the strategic review process

Company press release: ID:nACS0nvBqa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$500,000


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)